HPS-063 - Hypocalcemia incidence in denosumab use: A district hospital analysis

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-063
• By: LEE, Chun Hsien (Yuanlin Christian Hospital, Department of Pharmacy, Taiwan)
• Co-author(s): Mr Chun Hsien Lee (Yuanlin Christian Hospital, Department of Pharmacy, Changhua County, Taiwan)
  Mr Tsung Wei Chang (Yuanlin Christian Hospital, Department of Pharmacy, Changhua County, Taiwan)
  
• Abstract:

  Objectives
  Denosumab, a RANKL inhibitor, is widely used to manage bone health. It is marketed under two trade names: Prolia, approved by the FDA for treating osteoporosis, and Xgeva, indicated for cancer patients with bone metastases. Despite its efficacy, Denosumab is associated with serious side effects, such as hypocalcemia, which require..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login